List of Excipients in Branded Drug NATEGLINIDE

Generic Drugs Containing NATEGLINIDE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	nateglinide	0591-3354	FD&C RED NO. 40
Actavis Pharma Inc	nateglinide	0591-3354	FERRIC OXIDE RED
Actavis Pharma Inc	nateglinide	0591-3354	FERROSOFERRIC OXIDE
Actavis Pharma Inc	nateglinide	0591-3354	FUMARIC ACID

What are the Most Frequently-Used Excipients in NATEGLINIDE?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
1	CARNAUBA WAX
10	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE

Nateglinide Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Nateglinide is an oral insulin secretagogue in the meglitinide class, marketed originally as Starlix by Novartis for type 2 diabetes. Its commercial opportunity is now primarily generic and formulation-driven because the original product’s market exclusivity and core patent protection have expired or become commercially immaterial. The strongest opportunities are low-cost immediate-release tablets, orally disintegrating tablets, fixed-dose combinations, and differentiated products for patients requiring rapid, meal-linked glucose control.

The excipient strategy should prioritize rapid disintegration, reproducible dissolution, low manufacturing cost, moisture control, and compatibility with a short-acting active pharmaceutical ingredient. The reference product uses a conventional film-coated tablet platform with lactose, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, talc, and colloidal silicon dioxide as core excipients [1].

What is nateglinide and how does its formulation affect commercial value?

Nateglinide is a D-phenylalanine derivative that stimulates rapid, short-duration insulin release from pancreatic beta cells. It is administered before meals and is intended to reduce postprandial glucose excursions rather than provide sustained basal glycemic control [1,2].

Its formulation profile creates four commercial requirements:

Formulation requirement	Commercial rationale
Rapid tablet disintegration	Supports onset before or around the meal period
Consistent dissolution across physiological pH	Limits variability in exposure
Low tablet burden	Enables 60 mg and 120 mg strengths without excessive tablet size
Robust manufacturing process	Supports generic pricing and contract manufacturing

Nateglinide is absorbed rapidly after oral administration, with peak plasma concentrations generally reached within approximately one hour. Food can delay and reduce absorption, which supports administration shortly before meals and places greater importance on consistent tablet disintegration and dissolution [1].

The molecule is weakly acidic and has pH-dependent solubility characteristics. Excipient selection should therefore avoid unnecessary increases in microenvironmental pH or hydrophobic coating effects that could slow dissolution.

What excipients are used in the Starlix reference formulation?

The U.S. prescribing information identifies the following inactive ingredients for Starlix tablets:

Excipient	Likely function
Lactose monohydrate	Diluent and compressibility aid
Microcrystalline cellulose	Diluent, dry binder, tablet structure
Croscarmellose sodium	Superdisintegrant
Povidone	Binder
Magnesium stearate	Lubricant
Talc	Glidant and anti-adherent
Colloidal silicon dioxide	Glidant and flow aid
Film-coating components	Protection, appearance, swallowability, and product identification

The exact coating system should be confirmed against the applicable reference-product labeling and regulatory filings before development. The core excipient system is conventional and does not create a meaningful technical barrier for generic manufacturers.

The use of lactose and microcrystalline cellulose provides a familiar direct-compression or dry-granulation platform. Croscarmellose sodium is the most commercially important performance excipient in the formulation because rapid disintegration is aligned with nateglinide’s short-acting pharmacology.

How should a generic nateglinide tablet be designed?

A generic immediate-release tablet can use a reference-like formulation or a functionally equivalent alternative. The primary formulation target should be rapid and reproducible release rather than prolonged exposure.

Recommended excipient architecture

A practical development platform would contain:

• Nateglinide as the active ingredient
• Microcrystalline cellulose as the principal diluent
• Lactose monohydrate or mannitol as a secondary diluent
• Croscarmellose sodium or sodium starch glycolate as the disintegrant
• Povidone or copovidone as the binder
• Colloidal silicon dioxide as the glidant
• Magnesium stearate or sodium stearyl fumarate as the lubricant
• A conventional hypromellose-based film coating

The formulation should be optimized around tablet hardness, friability, disintegration time, dissolution profile, and content uniformity. Excess lubricant can reduce wettability and delay dissolution. Excess binder can increase tablet strength while slowing liquid penetration.

A direct-compression process is commercially attractive because it reduces equipment requirements and manufacturing steps. Dry granulation is a useful alternative when the active or excipient blend has poor flow, segregation risk, or inadequate compactability. Wet granulation is less attractive unless required by blend uniformity or mechanical-strength constraints because it adds processing cost and moisture exposure.

How should lactose intolerance and excipient preferences be addressed?

A lactose-free version could replace lactose monohydrate with mannitol, anhydrous dibasic calcium phosphate, or additional microcrystalline cellulose. Mannitol is particularly relevant for orally disintegrating tablets because it provides a cooling mouthfeel and acceptable palatability.

A lactose-free product would not necessarily provide a clinical advantage for most patients, but it could support institutional procurement, private-label differentiation, and markets where lactose-free labeling has commercial value.

What formulation patents protect nateglinide products?

Nateglinide’s principal commercial protection was associated with compound and pharmaceutical-use patents developed before the launch of Starlix. The central U.S. compound patent commonly associated with nateglinide is U.S. Patent No. 5,463,116, assigned to Ajinomoto and later relevant to the Novartis product platform. Its term expired before the current generic market period [3].

The patent landscape is now more relevant as a freedom-to-operate review than as a barrier to conventional generic tablets. A current product review should distinguish among:

1. Expired compound patents.
2. Expired formulation or process patents.
3. Any jurisdiction-specific later patents.
4. Patent claims covering combinations, dosage regimens, or manufacturing processes.
5. Third-party patents covering specialized excipients or delivery technologies.

A new patent could still arise from a genuinely differentiated formulation, but routine substitution of lactose, cellulose, croscarmellose sodium, or magnesium stearate is unlikely to produce strong composition-of-matter protection. Patent value would need to come from a measurable technical effect, such as improved stability, faster onset, reduced food sensitivity, improved adherence, or a clinically meaningful fixed-dose combination.

When did nateglinide lose exclusivity and what is the Orange Book status?

Nateglinide’s original regulatory and patent exclusivity period has ended. Starlix was approved by the FDA in December 2000, and the product is no longer protected by the exclusivity profile that supported branded pricing at launch [1,4].

Milestone	Approximate timing
U.S. approval of Starlix	December 2000
Original branded market period	Early 2000s
Core U.S. patent term expiration	Before the current generic period
Generic opportunity	Established
Current strategic focus	Cost, supply, formulation differentiation, and market access

The Orange Book should be checked for the current listed drug, approved abbreviated new drug applications, and any active patent certifications before filing or launch. Historical Orange Book listings and patent information do not substitute for a current regulatory review because listing status can change through delisting, product discontinuation, or updated FDA records [4].

A Paragraph IV challenge is therefore principally a historical issue for nateglinide. The commercial question today is whether an applicant can obtain approval and maintain competitive supply, not whether the core nateglinide molecule remains patent-blocked.

What generic entry risks exist for nateglinide?

Generic entry risk is high because the active ingredient is small-molecule, orally administered, and formulated as an immediate-release tablet. The likely approval route is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug [5].

The major risks are operational:

• Failure to match dissolution across relevant media.
• Content-uniformity problems at the lower 60 mg strength.
• Blend segregation from differences in particle size or density.
• Lubricant overmixing and delayed release.
• Stability loss caused by moisture or coating defects.
• Supply interruptions for lactose, microcrystalline cellulose, or disintegrants.
• Limited market size relative to the number of generic suppliers.

A formulation that is technically bioequivalent can still be commercially weak if it has a higher cost of goods, unreliable API supply, or no channel differentiation. Nateglinide is unlikely to support large development spending for a standard tablet unless the sponsor has an established diabetes portfolio or a low-cost manufacturing platform.

What excipient strategies create commercial opportunities?

1. Orally disintegrating tablets

An orally disintegrating tablet could target patients with swallowing difficulties, polypharmacy, or a need for administration immediately before eating. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and optimized superdisintegrant blends are suitable candidates.

The principal development challenge is dose loading. A 120 mg nateglinide tablet is feasible, but rapid disintegration, acceptable mouthfeel, and mechanical strength must be balanced. Taste masking may be necessary because nateglinide can create an undesirable oral sensory profile.

An ODT would need to demonstrate a meaningful patient or caregiver benefit. Faster disintegration alone may not create a strong clinical differentiation if gastrointestinal absorption remains the rate-limiting step.

2. Fast-release conventional tablets

A low-cost tablet with dissolution faster than the reference product could be commercially attractive if it maintains bioequivalence and avoids excessive variability. Crospovidone or croscarmellose sodium can be screened at multiple concentrations, with attention to tablet porosity and lubricant level.

This is the lowest-risk development path and is most suitable for a generic manufacturer seeking supply contracts rather than premium pricing.

3. Fixed-dose combinations

Nateglinide could be evaluated in combinations with metformin, although the commercial case is constrained by the dominance of metformin-based products and newer therapies such as GLP-1 receptor agonists and SGLT2 inhibitors. A combination with metformin would need to solve dosing flexibility because nateglinide is meal-linked while metformin is usually administered on a different schedule.

Potential advantages include reduced pill count and coordinated postprandial control. Potential disadvantages include more complex labeling, greater bioequivalence requirements, larger tablets, and limited prescribing momentum.

4. Modified-release or chronotherapeutic products

A modified-release nateglinide product would conflict with the drug’s pharmacologic role as a rapid, short-duration secretagogue. Sustained exposure could increase the risk of inappropriate insulin stimulation between meals and would require a new clinical and regulatory rationale.

The opportunity is therefore limited. A delayed-release or meal-triggered system would need evidence of improved postprandial efficacy or reduced hypoglycemia risk. Conventional extended-release technology is unlikely to be commercially compelling without such evidence.

5. Stability-enhancing excipient systems

Moisture-barrier packaging, low-moisture excipients, and robust film coatings may produce more reliable shelf life in hot and humid markets. These improvements are commercially relevant for emerging-market distribution, where temperature and humidity excursions are common.

The most practical approach is to combine a conventional core with high-barrier blister packaging rather than create a complex new formulation. Packaging may provide a stronger cost-benefit ratio than a novel excipient platform.

How strong is the patent estate for nateglinide formulation innovation?

The residual patent strength is low for standard immediate-release tablets and conventional excipient substitutions. A stronger patent position would require claims tied to a defined technical result.

Potentially defensible areas include:

Innovation area	Patent potential	Commercial value
Routine lactose-to-mannitol substitution	Low	Low to moderate
Specific rapid-disintegration composition	Moderate	Moderate
Taste-masked ODT	Moderate	Moderate
Improved humidity stability	Moderate	Moderate in selected markets
Novel fixed-dose combination	Moderate to high	Dependent on clinical adoption
New use or dosing regimen	Moderate	Requires clinical support
Novel delivery system	High in theory	High development cost

Patent claims should be supported by comparative data against the reference formulation. Useful evidence includes dissolution at multiple pH values, stability under accelerated conditions, disintegration time, pharmacokinetic variability, and patient-use data.

What FDA regulatory pathway applies to nateglinide products?

A standard generic tablet would generally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate sameness in active ingredient, dosage form, strength, route of administration, labeling, and performance, subject to FDA requirements [5].

A materially different formulation may require a 505(b)(2) application if it cannot rely fully on the reference product for safety and efficacy or if it introduces a new dosage form, delivery system, or clinical use. An ODT may still qualify for an ANDA if it meets applicable sameness and bioequivalence requirements, but a novel pharmacokinetic profile or therapeutic claim could increase regulatory complexity.

For a standard product, the development package should include:

• API characterization and impurity control.
• Excipient compatibility studies.
• Comparative dissolution.
• Stability data under ICH conditions.
• Bioequivalence testing.
• Container-closure qualification.
• Manufacturing process validation.
• Nitrosamine and elemental-impurity risk assessments where applicable.
• Updated labeling aligned with the reference product.

How does nateglinide compare with competing oral diabetes drugs?

Nateglinide competes against repaglinide, sulfonylureas, metformin, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists.

Product class	Dosing characteristic	Generic competition	Commercial implication
Nateglinide	Rapid, meal-linked	High	Low-cost niche opportunity
Repaglinide	Meal-linked, short acting	High	Direct therapeutic competitor
Sulfonylureas	Longer insulin stimulation	High	Lower-cost alternative
Metformin	Foundational therapy	Very high	Strong price pressure
DPP-4 inhibitors	Once daily for many products	Mixed	Better convenience
SGLT2 inhibitors	Once daily, cardiorenal positioning	Increasing	Stronger clinical differentiation
GLP-1 receptor agonists	Injectable or oral, weight-loss benefits	Lower for branded products	Higher-value but more complex market

Nateglinide’s advantage is dosing flexibility around meals. Its disadvantages are frequent administration, hypoglycemia risk, limited weight benefit, and weaker contemporary guideline positioning than several newer classes [2,6].

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve manufacturing and distribution than proprietary nateglinide technology. Potential transaction structures include:

• Regional rights for an approved generic tablet.
• Contract development and manufacturing of ODT or lactose-free products.
• Private-label supply to pharmacy chains.
• Portfolio licensing with metformin or other oral diabetes products.
• API and finished-dose supply agreements in emerging markets.
• Co-development of a fixed-dose combination.

A differentiated formulation could support a regional brand, but a global premium franchise is unlikely without clinical evidence or a broader diabetes portfolio. The commercial model should emphasize low development cost, reliable API sourcing, multi-market regulatory reuse, and manufacturing scale.

What revenue exposure and launch scenarios should investors model?

Nateglinide revenue exposure is likely to be modest for a single-product company because the molecule is generic and faces competition from multiple low-cost therapies. No standalone current revenue estimate should be attributed to the original branded product without company-specific disclosures.

Three launch scenarios are commercially relevant:

Scenario	Product	Likely economics
Commodity generic	60 mg and 120 mg immediate-release tablets	Low margin, volume dependent
Differentiated generic	ODT, lactose-free, or improved stability	Moderate price premium if channel accepts
Specialty repositioning	Fixed-dose or novel delivery product	Higher development cost and regulatory risk

The most defensible business case is a conventional tablet supported by efficient production and an ODT or lactose-free line extension. A novel modified-release product has the highest technical and clinical risk.

Key Takeaways

• Nateglinide is an established small-molecule diabetes drug with expired core exclusivity and a predominantly generic commercial profile.
• The reference formulation uses conventional excipients, including lactose, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, talc, and colloidal silicon dioxide.
• Rapid disintegration and reliable dissolution are the central formulation objectives.
• A direct-compression immediate-release tablet is the lowest-risk commercial route.
• ODT, lactose-free, taste-masked, and humidity-stable products offer the most credible differentiation.
• Fixed-dose combinations may reduce pill burden but face dosing and competitive challenges.
• Routine excipient substitutions have limited patent value.
• Stronger patent opportunities require comparative technical data and a defined performance advantage.
• The FDA pathway for a conventional generic is generally an ANDA.
• Commercial success will depend more on cost, supply reliability, geographic coverage, and channel access than on residual nateglinide patent protection.

FAQs

Is nateglinide still protected by patents?

The original compound and branded-product protection have expired or are no longer commercially blocking for standard generic development. Current Orange Book records and jurisdiction-specific patent databases should be reviewed before filing.

Which excipient is most important for nateglinide tablet performance?

Croscarmellose sodium or another effective superdisintegrant is central because nateglinide is a rapid-acting, meal-linked product. Lubricant concentration and mixing time also have a material effect on dissolution.

Can nateglinide be formulated as an orally disintegrating tablet?

Yes. Mannitol, crospovidone, croscarmellose sodium, and taste-masking technologies can support an ODT platform. Dose loading, mouthfeel, mechanical strength, and bioequivalence are the principal development issues.

Is a nateglinide-metformin combination commercially attractive?

It may reduce pill burden, but the opportunity is constrained by flexible dosing requirements, strong generic metformin competition, and the availability of newer diabetes therapies. The combination is more attractive as a portfolio or regional product than as a standalone global franchise.

What is the strongest commercial opportunity for nateglinide?

The strongest opportunity is a low-cost immediate-release generic with reliable supply, potentially followed by an ODT or lactose-free extension for selected markets. Novel modified-release products face a weaker risk-adjusted commercial case.

References

1. U.S. Food and Drug Administration. (2000). Starlix (nateglinide) tablets prescribing information. Novartis Pharmaceuticals Corporation.

2. American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Supplement 1), S158-S178.

3. United States Patent and Trademark Office. (1995). U.S. Patent No. 5,463,116: Benzylphenylalanine derivatives. Ajinomoto Co., Inc.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. Center for Drug Evaluation and Research.

6. Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., & Buse, J. B. (2022). Management of hyperglycaemia in type 2 diabetes, 2022: A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 45(11), 2753-2786.